help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hodsman, A. B.
Right arrow Articles by Drost, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hodsman, A. B.
Right arrow Articles by Drost, D.
The Journal of Clinical Endocrinology & Metabolism Vol. 82, No. 2 620-628
Copyright © 1997 by The Endocrine Society

Clinical Studies

A Randomized Controlled Trial to Compare the Efficacy of Cyclical Parathyroid Hormone Versus Cyclical Parathyroid Hormone and Sequential Calcitonin to Improve Bone Mass in Postmenopausal Women with Osteoporosis1

A. B. Hodsman, L. J. Fraher, P. H. Watson, T. Ostbye, L. W. Stitt, J. D. Adachi, D. H. Taves and D. Drost

Departments of Medicine (A.B.H., L.J.F., P.H.W.) and Radiology (D.H.T.) and Nuclear Medicine (D.D.), and the Lawson Research Institute (A.B.H., L.J.F., P.H.W.), St. Joseph’s Health Center, and the Department of Epidemiology and Biostatistics, University of Western Ontario (T.O., L.W.S.), London; and St. Joseph’s Hospital (J.D.A.), Hamilton, Ontario, Canada

Address all correspondence and requests for reprints to: Dr. A. B. Hodsman, Department of Medicine, St. Joseph’s Health Center, Room E-231, 268 Grosvenor Street, London, Ontario, Canada N6A 4V2.

Short cycles of human (h) PTH-(1–34) may have an anabolic effect to increase bone mass in patients with osteoporosis. As PTH also stimulates bone resorption, it is theoretically possible to enhance the anabolic effects of PTH by using a sequential antiresorptive agent in the treatment cycle. To test this hypothesis, 30 women with osteoporosis, aged 67 ± 8 yr, completed a 2-yr protocol that comprised 28-day courses of hPTH-(1–34) (800 U) given by daily sc injections; each course was repeated at 3-month intervals. By random allocation, patients either received sequential calcitonin (CT) immediately following the cycle of hPTH-(1–34) (75 U/day, sc; PTH+CT; n = 16) or placebo CT (PTH alone; n = 14) for 42 days. Baseline bone mineral density (BMD) at the lumbar spine site revealed t scores of -3.7 ± 1.2 (±SD) for the PTH alone group and -3.0 ± 1.4 for the PTH+CT groups, who had 2.0 ± 2.3 and 1.8 ± 2.4 vertebral fractures, respectively, at entry to the study.

At the end of the 2 yr, the lumbar spine BMD increased from 0.720 ± 0.130 to 0.793 ± 0.177 g/cm2 (10.2%) in the PTH group and from 0.760 ± 0.168 to 0.820 ± 0.149 g/cm2 (7.9%) in the PTH+CT group. These changes were significant over time in both groups (P < 0.001). Although the final 2-yr lumbar spine BMD was not significantly different between the two treatment groups, those patients receiving sequential CT injections gained bone mass at a consistently slower rate. Changes in BMD at the femoral neck averaged +2.4% and -1.8% in the PTH and PTH+CT groups, respectively, neither of which was significant. In the group receiving only cyclical hPTH-(1–34), the observed 2-yr vertebral fracture incidence was 4.5 compared to 23.0/100 patient yr in the PTH+CT group (P = 0.078). During the first two cycles, changes in biochemical markers of bone formation (serum total alkaline phosphatase, bone-specific alkaline phosphatase, and osteocalcin) and bone resorption (fasting urinary hydroxyproline and N-telopeptide excretion) were significantly increased over pretreatment values after 28 days of hPTH-(1–34) injections (P < 0.05 to P < 0.01 for both groups). Even end of cycle values remained elevated over the study baseline across time (P < 0.01). There were no significant differences for any outcome parameter between the two treatment groups. We conclude that short cycles (28 days) of daily hPTH-(1–34) injections result in significant increases in lumbar spine BMD, without significant changes in cortical bone mass at the femoral neck. Very low incident vertebral fracture rates were documented over 2 yr. However, there is no evidence that sequential antiresorptive therapy with CT is of any benefit over that conferred by cyclical PTH alone.




This article has been cited by other articles:


Home page
 EndocrinologyHome page
G. Cao, Z. Gu, Y. Ren, L. Shu, C. Tao, A. Karaplis, D. Goltzman, and D. Miao
Parathyroid Hormone Contributes to Regulating Milk Calcium Content and Modulates Neonatal Bone Formation Cooperatively with Calcium
Endocrinology, February 1, 2009; 150(2): 561 - 569.
[Abstract] [Full Text] [PDF]

Home page
 J Bone Joint Surg BrHome page
H. R. Johansson, R. Skripitz, and P. Aspenberg
Bisphosphonates can block the deterioration in implant fixation after withdrawal of intermittent doses of parathyroid hormone
J Bone Joint Surg Br, March 1, 2008; 90-B(3): 400 - 404.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
A. Cranney, A. Papaioannou, N. Zytaruk, D. Hanley, J. Adachi, D. Goltzman, T. Murray, A. Hodsman, and for the Clinical Guidelines Committee of Osteoporo
Parathyroid hormone for the treatment of osteoporosis: a systematic review.
Can. Med. Assoc. J., July 4, 2006; 175(1): 52 - 59.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
A. J. Koh, B. Demiralp, K. G. Neiva, J. Hooten, R. M. Nohutcu, H. Shim, N. S. Datta, R. S. Taichman, and L. K. McCauley
Cells of the Osteoclast Lineage as Mediators of the Anabolic Actions of Parathyroid Hormone in Bone
Endocrinology, November 1, 2005; 146(11): 4584 - 4596.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S. P Shrader and K. R Ragucci
Parathyroid Hormone (1-84) and Treatment of Osteoporosis
Ann. Pharmacother., September 1, 2005; 39(9): 1511 - 1516.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
A. B. Hodsman, D. C. Bauer, D. W. Dempster, L. Dian, D. A. Hanley, S. T. Harris, D. L. Kendler, M. R. McClung, P. D. Miller, W. P. Olszynski, et al.
Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its Use
Endocr. Rev., August 1, 2005; 26(5): 688 - 703.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. Dobnig, A. Sipos, Y. Jiang, A. Fahrleitner-Pammer, L.-G. Ste-Marie, J. C. Gallagher, I. Pavo, J. Wang, and E. F. Eriksen
Early Changes in Biochemical Markers of Bone Formation Correlate with Improvements in Bone Structure during Teriparatide Therapy
J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 3970 - 3977.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. C. Buxton, W. Yao, and N. E. Lane
Changes in Serum Receptor Activator of Nuclear Factor-{kappa}B Ligand, Osteoprotegerin, and Interleukin-6 Levels in Patients with Glucocorticoid-Induced Osteoporosis Treated with Human Parathyroid Hormone (1-34)
J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3332 - 3336.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
O. Gluck and G. Colice
Recognizing and Treating Glucocorticoid-Induced Osteoporosis in Patients With Pulmonary Diseases
Chest, May 1, 2004; 125(5): 1859 - 1876.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
K. A Cappuzzo and J. C Delafuente
Teriparatide for Severe Osteoporosis
Ann. Pharmacother., February 1, 2004; 38(2): 294 - 302.
[Abstract] [Full Text] [PDF]

Home page
 Clin. DiabetesHome page
S. A. Brown and J. L. Sharpless
Osteoporosis: An Under-appreciated Complication of Diabetes
Clin. Diabetes, January 1, 2004; 22(1): 10 - 20.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. B. Hodsman, D. A. Hanley, M. P. Ettinger, M. A. Bolognese, J. Fox, A. J. Metcalfe, and R. Lindsay
Efficacy and Safety of Human Parathyroid Hormone-(1-84) in Increasing Bone Mineral Density in Postmenopausal Osteoporosis
J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5212 - 5220.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. S. Finkelstein, A. Hayes, J. L. Hunzelman, J. J. Wyland, H. Lee, and R. M. Neer
The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis
N. Engl. J. Med., September 25, 2003; 349(13): 1216 - 1226.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
J. P. Brown and R. G. Josse
Lignes directrices de pratique clinique 2002 pour le diagnostic et le traitement de l'osteoporose au Canada
Can. Med. Assoc. J., March 18, 2003; 168(90060): SF1 - 38.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
B. M. Misof, P. Roschger, F. Cosman, E. S. Kurland, W. Tesch, P. Messmer, D. W. Dempster, J. Nieves, E. Shane, P. Fratzl, et al.
Effects of Intermittent Parathyroid Hormone Administration on Bone Mineralization Density in Iliac Crest Biopsies from Patients with Osteoporosis: A Paired Study before and after Treatment
J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1150 - 1156.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. J. Horwitz, M. B. Tedesco, C. Gundberg, A. Garcia-Ocana, and A. F. Stewart
Short-Term, High-Dose Parathyroid Hormone-Related Protein as a Skeletal Anabolic Agent for the Treatment of Postmenopausal Osteoporosis
J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 569 - 575.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
J. P. Brown and R. G. Josse
2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada
Can. Med. Assoc. J., November 12, 2002; 167(90100): s1 - 34.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
C. Crandall
Parathyroid Hormone for Treatment of Osteoporosis
Arch Intern Med, November 11, 2002; 162(20): 2297 - 2309.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
A. Cranney, P. Tugwell, N. Zytaruk, V. Robinson, B. Weaver, B. Shea, G. Wells, J. Adachi, L. Waldegger, and G. Guyatt
VI. Meta-Analysis of Calcitonin for the Treatment of Postmenopausal Osteoporosis
Endocr. Rev., August 1, 2002; 23(4): 540 - 551.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Minagawa, T. Yasuda, T. Watanabe, K. Minamitani, Y. Takahashi, D. Goltzman, J. H. White, G. N. Hendy, and Y. Kohno
Association between AAAG Repeat Polymorphism in the P3 Promoter of the Human Parathyroid Hormone (PTH)/PTH-Related Peptide Receptor Gene and Adult Height, Urinary Pyridinoline Excretion, and Promoter Activity
J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1791 - 1796.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. F. Nemeth, E. G. Delmar, W. L. Heaton, M. A. Miller, L. D. Lambert, R. L. Conklin, M. Gowen, J. G. Gleason, P. K. Bhatnagar, and J. Fox
Calcilytic Compounds: Potent and Selective Ca2+ Receptor Antagonists That Stimulate Secretion of Parathyroid Hormone
J. Pharmacol. Exp. Ther., October 1, 2001; 299(1): 323 - 331.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
P. J. Kostenuik, C. Capparelli, S. Morony, S. Adamu, G. Shimamoto, V. Shen, D. L. Lacey, and C. R. Dunstan
OPG and PTH-(1-34) Have Additive Effects on Bone Density and Mechanical Strength in Osteopenic Ovariectomized Rats
Endocrinology, October 1, 2001; 142(10): 4295 - 4304.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
D. Altkorn and T. Vokes
Treatment of Postmenopausal Osteoporosis
JAMA, March 21, 2001; 285(11): 1415 - 1418.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. S. Kurland, F. Cosman, D. J. McMahon, C. J. Rosen, R. Lindsay, and J. P. Bilezikian
Parathyroid Hormone as a Therapy for Idiopathic Osteoporosis in Men: Effects on Bone Mineral Density and Bone Markers
J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3069 - 3076.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Horwitz, A. Stewart, and S. L. Greenspan
Editorial: Sequential Parathyroid Hormone/Alendronate Therapy for Osteoporosis--Robbing Peter to Pay Paul?
J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2127 - 2128.
[Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. S. Rittmaster, M. Bolognese, M. P. Ettinger, D. A. Hanley, A. B. Hodsman, D. L. Kendler, and C. J. Rosen
Enhancement of Bone Mass in Osteoporotic Women with Parathyroid Hormone followed by Alendronate
J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2129 - 2134.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. Brommage, C. E. Hotchkiss, C. J. Lees, M. W. Stancill, J. M. Hock, and C. P. Jerome
Daily Treatment with Human Recombinant Parathyroid Hormone-(1-34), LY333334, for 1 Year Increases Bone Mass in Ovariectomized Monkeys
J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3757 - 3763.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. J. Fraher, R. Avram, P. H. Watson, G. N. Hendy, J. E. Henderson, K. L. Chong, D. Goltzman, P. Morley, G. E. Willick, J. F. Whitfield, et al.
Comparison of the Biochemical Responses to Human Parathyroid Hormone-(1-31)NH2 and hPTH-(1-34) in Healthy Humans
J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2739 - 2743.
[Abstract] [Full Text]

Home page
 JAMAHome page
J. S. Finkelstein, A. Klibanski, A. L. Arnold, T. L. Toth, M. D. Hornstein, and R. M. Neer
Prevention of Estrogen Deficiency-Related Bone Loss With Human Parathyroid Hormone-(1-34): A Randomized Controlled Trial
JAMA, September 23, 1998; 280(12): 1067 - 1073.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. Plotkin, C. Gundberg, M. Mitnick, and A. F. Stewart
Dissociation of Bone Formation from Resorption during 2-Week Treatment with Human Parathyroid Hormone-Related Peptide-(1-36) in Humans: Potential as an Anabolic Therapy for Osteoporosis
J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2786 - 2791.
[Abstract] [Full Text]

Home page
 NEJMHome page
R. Eastell
Treatment of Postmenopausal Osteoporosis
N. Engl. J. Med., March 12, 1998; 338(11): 736 - 746.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1997 by The Endocrine Society